van Det R J, Vriens B H R, van der Palen J, Geelkerken R H
Department of Vascular Surgery, Medisch Spectrum Twente Hospital, PO Box 50.000, 7500 KA Enschede, The Netherlands.
Eur J Vasc Endovasc Surg. 2009 Apr;37(4):457-63. doi: 10.1016/j.ejvs.2008.11.041. Epub 2009 Feb 20.
To compare expanded polytetrafluoroethylene (ePTFE) prosthesis and collagen-impregnated knitted polyester (Dacron) for above-knee (AK) femoro-popliteal bypass grafts.
A prospective multicentre randomised clinical trial.
Between 1992 and 1996, 228 AK femoro-popliteal bypass grafts were randomly allocated to either an ePTFE (n=114) or a Dacron (n=114) vascular graft (6mm in diameter). Patients were eligible for inclusion if presenting with disabling claudication, rest pain or tissue loss. Follow-up was performed and included clinical examination and duplex ultrasonography at all scheduled intervals. All patients were treated with warfarin. The main end-point of this study was primary patency of the bypass graft at 2, 5 and 10 years after implantation. Secondary end-points were mortality, primary assisted patency and secondary patency. Cumulative patency rates were calculated with life-table analysis and with log-rank test.
After 5 years, the primary, primary assisted and secondary patency rates were 36% (confidence interval (CI): 26-46%), 46% (CI: 36-56%) and 51% (CI: 41-61%) for ePTFE and 52% (CI: 42-62%) (p=0.04), 66% (CI: 56-76%) (p=0.01) and 70% (CI: 60-80%) (p=0.01) for Dacron, respectively. After ten years these rates were respectively 28% (CI:18-38%), 31% (CI:19-43%) and 35% (CI: 23-47%) for ePTFE and 28% (CI: 18-38%), 49% (CI: 37-61%) and 49% (CI: 37-61%) for Dacron.
During prolonged follow-up (10 years), Dacron femoro-popliteal bypass grafts have superior patency compared to those of ePTFE grafts. Dacron is the graft material of choice if the saphenous vein is not available.
比较膨体聚四氟乙烯(ePTFE)人工血管与胶原浸渍针织聚酯(涤纶)人工血管用于膝上股腘动脉搭桥术的效果。
一项前瞻性多中心随机临床试验。
1992年至1996年间,228例膝上股腘动脉搭桥术患者被随机分配至ePTFE组(n = 114)或涤纶组(n = 114),使用直径6mm的血管移植物。出现致残性间歇性跛行、静息痛或组织缺损的患者符合纳入标准。定期进行随访,包括临床检查和双功超声检查。所有患者均接受华法林治疗。本研究的主要终点是植入后2年、5年和10年时搭桥移植物的原发性通畅率。次要终点是死亡率、原发性辅助通畅率和继发性通畅率。采用寿命表分析和对数秩检验计算累积通畅率。
5年后,ePTFE组的原发性、原发性辅助性和继发性通畅率分别为36%(置信区间(CI):26 - 46%)、46%(CI:36 - 56%)和51%(CI:41 - 61%),涤纶组分别为52%(CI:42 - 62%)(p = 0.04)、66%(CI:56 - 76%)(p = 0.01)和70%(CI:60 - 80%)(p = 0.01)。10年后,ePTFE组的这些比率分别为28%(CI:18 - 38%)、31%(CI:19 - 43%)和35%(CI:23 - 47%),涤纶组分别为28%(CI:18 - 38%)、49%(CI:37 - 61%)和49%(CI:37 - 61%)。
在长期随访(10年)中,涤纶股腘动脉搭桥移植物的通畅性优于ePTFE移植物。如果没有大隐静脉,涤纶是首选的移植物材料。